JP2017531659A - Ｐｅｇ化リポソームおよび血液凝固因子の製剤処方 - Google Patents

Ｐｅｇ化リポソームおよび血液凝固因子の製剤処方 Download PDF

Info

Publication number
JP2017531659A
JP2017531659A JP2017518466A JP2017518466A JP2017531659A JP 2017531659 A JP2017531659 A JP 2017531659A JP 2017518466 A JP2017518466 A JP 2017518466A JP 2017518466 A JP2017518466 A JP 2017518466A JP 2017531659 A JP2017531659 A JP 2017531659A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
factor
composition according
blood
colloidal particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017518466A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531659A5 (enExample
Inventor
ヘンリー，ウィリアム
Original Assignee
カンタブ バイオファーマシューティカルズ パテンツ リミテッド
カンタブ バイオファーマシューティカルズ パテンツ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カンタブ バイオファーマシューティカルズ パテンツ リミテッド, カンタブ バイオファーマシューティカルズ パテンツ リミテッド filed Critical カンタブ バイオファーマシューティカルズ パテンツ リミテッド
Publication of JP2017531659A publication Critical patent/JP2017531659A/ja
Publication of JP2017531659A5 publication Critical patent/JP2017531659A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2017518466A 2014-10-06 2015-10-06 Ｐｅｇ化リポソームおよび血液凝固因子の製剤処方 Pending JP2017531659A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1417589.7A GB201417589D0 (en) 2014-10-06 2014-10-06 Pharmaceutical Formulations
GB1417589.7 2014-10-06
PCT/EP2015/073003 WO2016055447A1 (en) 2014-10-06 2015-10-06 Pharmaceutical formulations of pegylated liposomes and blood coagulation factors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020129101A Division JP2020183446A (ja) 2014-10-06 2020-07-30 Ｐｅｇ化リポソームおよび血液凝固因子の製剤処方

Publications (2)

Publication Number Publication Date
JP2017531659A true JP2017531659A (ja) 2017-10-26
JP2017531659A5 JP2017531659A5 (enExample) 2018-11-15

Family

ID=51946871

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017518466A Pending JP2017531659A (ja) 2014-10-06 2015-10-06 Ｐｅｇ化リポソームおよび血液凝固因子の製剤処方
JP2020129101A Pending JP2020183446A (ja) 2014-10-06 2020-07-30 Ｐｅｇ化リポソームおよび血液凝固因子の製剤処方
JP2022168146A Active JP7573582B2 (ja) 2014-10-06 2022-10-20 Ｐｅｇ化リポソームおよび血液凝固因子の製剤処方

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020129101A Pending JP2020183446A (ja) 2014-10-06 2020-07-30 Ｐｅｇ化リポソームおよび血液凝固因子の製剤処方
JP2022168146A Active JP7573582B2 (ja) 2014-10-06 2022-10-20 Ｐｅｇ化リポソームおよび血液凝固因子の製剤処方

Country Status (16)

Country Link
US (2) US20170304203A1 (enExample)
EP (1) EP3204034B9 (enExample)
JP (3) JP2017531659A (enExample)
AU (1) AU2015330102B2 (enExample)
BR (1) BR112017007031A2 (enExample)
CA (1) CA2994891C (enExample)
ES (1) ES2954134T3 (enExample)
GB (1) GB201417589D0 (enExample)
HR (1) HRP20230985T1 (enExample)
HU (1) HUE063656T2 (enExample)
MX (1) MX384517B (enExample)
PL (1) PL3204034T3 (enExample)
RS (1) RS64461B1 (enExample)
RU (1) RU2737291C2 (enExample)
SM (1) SMT202300271T1 (enExample)
WO (1) WO2016055447A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
JP6825010B2 (ja) * 2016-05-26 2021-02-03 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 遠心法によるリポソーム調製のための方法及び装置

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512947A (ja) * 1998-04-27 2002-05-08 オッパーバス・ホールディング・ビー・ブイ 第ｖｉｉｉ因子及び中性リポソームを含有する薬学的組成物
JP2003531862A (ja) * 2000-05-03 2003-10-28 ノボ ノルディスク アクティーゼルスカブ 凝固因子ｖｉｉの皮下投与
JP2006523683A (ja) * 2003-04-15 2006-10-19 オッパーバス・ホールディング・ビー・ブイ タンパク質及び／またはポリペプチド及びコロイド粒子を含む医薬組成物
JP2008544990A (ja) * 2005-06-29 2008-12-11 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 低免疫原性蛋白質−脂質複合体に関する組成物および方法
JP2010514819A (ja) * 2007-01-03 2010-05-06 ノボ ノルディスク ヘルス ケア アーゲー 凝固第ｖｉｉ因子関連ポリペプチドの皮下投与
JP2013525415A (ja) * 2010-04-30 2013-06-20 カンタブ バイオファーマシューティカルズ パテンツ リミテッド 共役血液凝固第ＶＩＩａ因子
WO2013156488A2 (en) * 2012-04-16 2013-10-24 Leverton Licence Holdings Limited Optimised subcutaneous therapeutic agents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6326353B1 (en) 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
DE69418334T2 (de) 1993-08-06 2000-01-27 Opperbas Holding B.V., Amsterdam Verfahren zur hohen beladung von vesikeln mit biopolymeren substanzen
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6156337A (en) * 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
RU2250911C2 (ru) * 1999-07-14 2005-04-27 Элзэ Копэрейшн Липосомальная композиция, нейтральный липополимер и способ увеличения времени циркуляции липосомы
US20030232075A1 (en) 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
CA2701884A1 (en) 2007-10-15 2009-04-23 Wake Forest University Health Sciences Methods and compositions for printing biologically compatible nanotube composites of autologous tissue
AU2010255391C1 (en) 2009-06-03 2016-10-27 Sequessome Technology Holdings Limited Formulations for the treatment of deep tissue pain
MX336482B (es) 2009-08-21 2016-01-21 Henk-Andre Kroon Formulaciones vesiculares.
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
TW201240664A (en) * 2010-09-01 2012-10-16 Portola Pharm Inc Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512947A (ja) * 1998-04-27 2002-05-08 オッパーバス・ホールディング・ビー・ブイ 第ｖｉｉｉ因子及び中性リポソームを含有する薬学的組成物
JP2003531862A (ja) * 2000-05-03 2003-10-28 ノボ ノルディスク アクティーゼルスカブ 凝固因子ｖｉｉの皮下投与
JP2006523683A (ja) * 2003-04-15 2006-10-19 オッパーバス・ホールディング・ビー・ブイ タンパク質及び／またはポリペプチド及びコロイド粒子を含む医薬組成物
JP2008544990A (ja) * 2005-06-29 2008-12-11 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 低免疫原性蛋白質−脂質複合体に関する組成物および方法
JP2010514819A (ja) * 2007-01-03 2010-05-06 ノボ ノルディスク ヘルス ケア アーゲー 凝固第ｖｉｉ因子関連ポリペプチドの皮下投与
JP2013525415A (ja) * 2010-04-30 2013-06-20 カンタブ バイオファーマシューティカルズ パテンツ リミテッド 共役血液凝固第ＶＩＩａ因子
WO2013156488A2 (en) * 2012-04-16 2013-10-24 Leverton Licence Holdings Limited Optimised subcutaneous therapeutic agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARU MOSHE: "FACTOR VIII EFFICIENT AND SPECIFIC NON-COVALENT BINDING TO PEGYLATED LIPOSOMES ENABLES 以下備考", THROMBOSIS AND HAEMOSTASIS, vol. VOL:93, NR:6, JPN5017009042, June 2005 (2005-06-01), DE, pages 1061 - 1068, ISSN: 0004084974 *
PAN, JUNLIANG ET AL., BLOOD, vol. 114, no. 13, JPN6019029240, 4 August 2009 (2009-08-04), pages 2802 - 2811, ISSN: 0004084975 *
PENG, AARON ET AL., THE AAPS JOURNAL, vol. 14, no. 1, JPN6019029237, March 2012 (2012-03-01), pages 35 - 42, ISSN: 0004240678 *
RAMANI, KARTHIK ET AL., JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 97, no. 9, JPN6019029242, September 2008 (2008-09-01), pages 3753 - 3764, ISSN: 0004240677 *

Also Published As

Publication number Publication date
HUE063656T2 (hu) 2024-01-28
JP7573582B2 (ja) 2024-10-25
JP2023002687A (ja) 2023-01-10
AU2015330102A1 (en) 2017-05-25
RS64461B1 (sr) 2023-09-29
EP3204034A1 (en) 2017-08-16
CA2994891A1 (en) 2016-04-14
CA2994891C (en) 2023-04-04
US20170304203A1 (en) 2017-10-26
HRP20230985T1 (hr) 2023-12-08
WO2016055447A1 (en) 2016-04-14
EP3204034B9 (en) 2023-10-04
EP3204034C0 (en) 2023-06-07
US11484499B2 (en) 2022-11-01
RU2017115831A3 (enExample) 2019-05-06
RU2017115831A (ru) 2018-11-14
US20190060235A1 (en) 2019-02-28
MX384517B (es) 2025-03-14
EP3204034B1 (en) 2023-06-07
SMT202300271T1 (it) 2023-09-06
ES2954134T3 (es) 2023-11-20
GB201417589D0 (en) 2014-11-19
MX2017004378A (es) 2018-02-09
JP2020183446A (ja) 2020-11-12
PL3204034T3 (pl) 2023-11-06
BR112017007031A2 (pt) 2018-01-30
AU2015330102B2 (en) 2021-01-28
RU2737291C2 (ru) 2020-11-26

Similar Documents

Publication Publication Date Title
US20250170244A1 (en) Colloidal particles for use in medicine
JP7573582B2 (ja) Ｐｅｇ化リポソームおよび血液凝固因子の製剤処方
JP2024532164A (ja) 血友病ａの治療における使用のための修飾コロイド粒子
WO2017064289A1 (en) Colloidal particles for topical administration with therapeutic agent
WO2017064300A1 (en) Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
US20240358801A1 (en) Modified colloidal particles for use in the treatment of haemophilia a
US20250064738A1 (en) Modified colloidal particles for use in the treatment of haemophilia a

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200331